Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115


An open-label, single arm, phase III clinical study to evaluate the efficacy and safety of CJ smallpox vaccine in previously vaccinated healthy adults.

Kim NH, Kang YM, Kim G, Choe PG, Song JS, Lee KH, Seong BL, Park WB, Kim NJ, Oh MD.

Vaccine. 2013 Oct 25;31(45):5239-42. doi: 10.1016/j.vaccine.2013.08.071. Epub 2013 Sep 8.


A randomized, double-blind, controlled clinical trial to evaluate the efficacy and safety of CJ-50300, a newly developed cell culture-derived smallpox vaccine, in healthy volunteers.

Jang HC, Kim CJ, Kim KH, Lee KH, Byun YH, Seong BL, Saletti G, Czerkinsky C, Park WB, Park SW, Kim HB, Kim NJ, Oh MD.

Vaccine. 2010 Aug 16;28(36):5845-9. doi: 10.1016/j.vaccine.2010.06.063. Epub 2010 Jun 30.


Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects.

Greenberg RN, Overton ET, Haas DW, Frank I, Goldman M, von Krempelhuber A, Virgin G, Bädeker N, Vollmar J, Chaplin P.

J Infect Dis. 2013 Mar 1;207(5):749-58. doi: 10.1093/infdis/jis753. Epub 2012 Dec 7.


Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC).

Wharton M, Strikas RA, Harpaz R, Rotz LD, Schwartz B, Casey CG, Pearson ML, Anderson LJ; Advisory Committee on Immunization Practices; Healthcare Infection Control Practices Advisory Committee.

MMWR Recomm Rep. 2003 Apr 4;52(RR-7):1-16.


Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8.

Saito T, Fujii T, Kanatani Y, Saijo M, Morikawa S, Yokote H, Takeuchi T, Kuwabara N.

JAMA. 2009 Mar 11;301(10):1025-33. doi: 10.1001/jama.2009.289.


Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis.

von Sonnenburg F, Perona P, Darsow U, Ring J, von Krempelhuber A, Vollmar J, Roesch S, Baedeker N, Kollaritsch H, Chaplin P.

Vaccine. 2014 Sep 29;32(43):5696-702. doi: 10.1016/j.vaccine.2014.08.022. Epub 2014 Aug 20.


Response to smallpox vaccine in persons immunized in the distant past.

Frey SE, Newman FK, Yan L, Lottenbach KR, Belshe RB.

JAMA. 2003 Jun 25;289(24):3295-9. Erratum in: JAMA. 2003 Jul 16;290(3):334.


Vaccines for preventing smallpox.

Metzger W, Mordmueller BG.

Cochrane Database Syst Rev. 2007 Jul 18;(3):CD004913. Review.


Freeze-dried live attenuated smallpox vaccine prepared in cell culture "LC16-KAKETSUKEN": Post-marketing surveillance study on safety and efficacy compliant with Good Clinical Practice.

Nishiyama Y, Fujii T, Kanatani Y, Shinmura Y, Yokote H, Hashizume S.

Vaccine. 2015 Nov 9;33(45):6120-7. doi: 10.1016/j.vaccine.2015.09.067. Epub 2015 Oct 9.


The persistence of humoral and cellular immunities more than three decades after smallpox vaccination.

Kim SH, Yeo SG, Park KH, Bang JW, Kim HB, Kim NJ, Jee Y, Cho H, Oh MD, Choe KW.

Clin Microbiol Infect. 2007 Jan;13(1):91-3.


Expected adverse events in a mass smallpox vaccination campaign.

Kemper AR, Davis MM, Freed GL.

Eff Clin Pract. 2002 Mar-Apr;5(2):84-90.


A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.

von Krempelhuber A, Vollmar J, Pokorny R, Rapp P, Wulff N, Petzold B, Handley A, Mateo L, Siersbol H, Kollaritsch H, Chaplin P.

Vaccine. 2010 Feb 3;28(5):1209-16. doi: 10.1016/j.vaccine.2009.11.030. Epub 2009 Nov 25.


Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine.

Vollmar J, Arndtz N, Eckl KM, Thomsen T, Petzold B, Mateo L, Schlereth B, Handley A, King L, Hülsemann V, Tzatzaris M, Merkl K, Wulff N, Chaplin P.

Vaccine. 2006 Mar 15;24(12):2065-70. Epub 2005 Nov 28.


Dose-related effects of smallpox vaccine.

Frey SE, Newman FK, Cruz J, Shelton WB, Tennant JM, Polach T, Rothman AL, Kennedy JS, Wolff M, Belshe RB, Ennis FA.

N Engl J Med. 2002 Apr 25;346(17):1275-80. Epub 2002 Mar 28.


Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine: a randomized controlled trial.

Talbot TR, Stapleton JT, Brady RC, Winokur PL, Bernstein DI, Germanson T, Yoder SM, Rock MT, Crowe JE Jr, Edwards KM.

JAMA. 2004 Sep 8;292(10):1205-12. Erratum in: JAMA. 2004 Nov 24;292(20):2470.


Alternative immunological markers to document successful multiple smallpox revaccinations.

Wiser I, Orr N, Smetana Z, Spungin-Bialik A, Mendelson E, Cohen D.

Clin Infect Dis. 2011 Apr 1;52(7):856-61. doi: 10.1093/cid/cir006.


Vaccination-Related Side Effects, Humoral Immunity, and Adverse Events during the Civilian Smallpox Vaccination Campaign, Arkansas, 2003.

Haselow D.

Public Health Nurs. 2016 Mar-Apr;33(2):129-38. doi: 10.1111/phn.12208. Epub 2015 Jun 4.


Clinical responses to smallpox vaccine in vaccinia-naive and previously vaccinated populations: undiluted and diluted Lancy-Vaxina vaccine in a single-blind, randomized, prospective trial.

Kim SH, Yeo SG, Jang HC, Park WB, Lee CS, Lee KD, Kim HB, Kim NJ, Kim YT, Jee Y, Cho H, Oh MD, Choe KW.

J Infect Dis. 2005 Sep 15;192(6):1066-70. Epub 2005 Aug 11.


Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults.

Frey SE, Newman FK, Kennedy JS, Ennis F, Abate G, Hoft DF, Monath TP.

Vaccine. 2009 Mar 4;27(10):1637-44. doi: 10.1016/j.vaccine.2008.11.079. Epub 2008 Dec 9.


Demographic and clinical factors associated with response to smallpox vaccine in preimmunized volunteers.

Bossi P, Gay F, Fouzai I, Combadière B, Brousse G, Lebrun-Vignes B, Crance JM, Autran B, Garin D.

PLoS One. 2008;3(12):e4087. doi: 10.1371/journal.pone.0004087. Epub 2008 Dec 31.

Items per page

Supplemental Content

Write to the Help Desk